P&G wins patent lawsuit for osteoporosis therapy against Teva
Feb 28 (Reuters) - Procter & Gamble Co (PG.N: Quote, Profile, Research, Stock Buzz) said it won a patent infringement lawsuit for osteoporosis therapy Actonel against Teva Pharmaceuticals USA Inc.
Procter & Gamble said the ruling of U.S. District Court of Delaware protects P&G's rights in the U.S. to exclusively market the osteoporosis therapy Actonel. The ruling upheld the P&G patent, rejecting Teva's validity challenge, it added.
The Actonel patent life extends through the end of 2013, excluding any potential extensions, P&G said in a statement. (Reporting by Dilipp S. Nag in Bangalore; Editing by Anil D'Silva)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Sphere
Piracy fight
Obama visits Jewish shrine